US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.16 against a street estimate of 0.15 — a beat of 6.7%.
Analysts rate Stevanato Group SpA a buy (8 buy, 3 hold, 0 sell out of 11) with an average price target of $24.68.
CONFIDENT STVN delivered Q2 revenue growth of 8% YoY to €302M with 26% adjusted EBITDA margin. High-value solutions grew 16%, driven by biologics. Alina device gained European approval; divestiture of non-core Balda C. Brewer completed. Full-year guidance raised modestly on currency tailwinds and organic growth. Q2 FY26 Alina approvals in multiple European countries; North American approvals expected H2 2026. Fishers (US) and Latina (Italy) expansion on track. Analysts pushed on segment growth attribution (GLP vs. non-GLP biologics), Alina upside, and Engineering stabilization. Management emphasized biologics as durable tailwind beyond single GLP class and highlighted approvals as catalyst for biosimilar validation. Engineering margins improved 370 bps despite revenue decline; optimization plan credited. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Conestoga Capital Advisors, LLC | 2.57% |
| Neuberger Berman Group LLC | 1.64% |
| TimesSquare Capital Management, LLC | 1.27% |
| T. Rowe Price Investment Management,Inc. | 1.18% |
| Van Berkom and Associates Inc | 1.09% |
| Artisan Partners Limited Partnership | 0.95% |
| BAMCO Inc | 0.92% |
| Morgan Stanley - Brokerage Accounts | 0.48% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.06 / share ex-date Jun 11, 2026 · pay Jul 29, 2026 | 2026-06-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stevanato Group SpA — free to start.
Google PlayApp StoreData updated 2026-09-18.